Pancreatic cancer survival doubled by targeting KRAS mutations—systemic inequities in drug access persist despite breakthrough
Original framing: “Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease” — The Conversation - Global
Daraxonrasib targets the KRAS G12D mutation, a driver in ~90% of pancreatic ductal adenocarcinomas, by inhibiting the protein’s active state, a mechanism validated through X-ray crystallography and preclinical models. The drug’s efficacy (nearly doubling median survival to ~12 months) is grounded in rigorous phase I/II trials, but long-term safety and resistance mechanisms remain understudied. The focus on KRAS ignores other pathways (e.g., p53, BRCA) and the tumor microenvironment’s role in metastasis, which may limit durability of response.
The daraxonrasib breakthrough exemplifies how biomedical innovation, while life-extending, is constrained by market logics that prioritize late-stage interventions over prevention and equity.
The 30-year delay in translating KRAS research into a viable drug reflects systemic failures in translational medicine, where public funding is diverted to profit-driven priorities. Marginalized communities—already burdened by environmental racism and food apartheid—are excluded from both the benefits of such drugs and the decision-making processes that shape their development. Indigenous knowledge systems, with their holistic approaches to cancer care, offer complementary pathways that challenge the biomedical paradigm’s narrow focus on pharmacological solutions. A systemic response requires integrating traditional wisdom, reforming clinical trial design, and restructuring healthcare to address root causes of disease, not just their symptoms. The trickster’s irony lies in the fact that while daraxonrasib nearly doubles survival for some, it does little to address the preventable conditions that make pancreatic cancer a leading killer in the first place.